These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36119229)

  • 21. Adverse event following vaccine surveillance in Kaduna State, Northwestern Nigeria (January 2018 -June 2019): analysis of health facility´s records.
    Ishaku SG; Umeh G; Adzu B; Onimisi A; Dauda M; Iyal HA; Iliyasu N; Sunday DJ; Daikwo J; Yates SM; Ibrahim II; Samaila LH; Abdullahi B; Parom SK; Maiwashi KY; Zakari F; Nuhu KS
    Pan Afr Med J; 2021; 40():268. PubMed ID: 35251462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of associated events following AZD1222 (Covishield) vaccination in a high-risk population in Nepal.
    Poudel KM; Shah N; Prakash M; Deo SK; Bhandari S; Poudel TR
    BMC Infect Dis; 2022 May; 22(1):422. PubMed ID: 35505278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon.
    Ateudjieu J; Stoll B; Nguefack-Tsague G; Yakum MN; Mengouo MN; Genton B
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1170-1178. PubMed ID: 27174237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postmarketing Safety Monitoring After Influenza Vaccination Using a Mobile Health App: Prospective Longitudinal Feasibility Study.
    Nguyen MTH; Krause G; Keller-Stanislawski B; Glöckner S; Mentzer D; Ott JJ
    JMIR Mhealth Uhealth; 2021 May; 9(5):e26289. PubMed ID: 33960950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study.
    Kamal D; Thakur V; Nath N; Malhotra T; Gupta A; Batlish R
    Med J Armed Forces India; 2021 Jul; 77(Suppl 2):S283-S288. PubMed ID: 34334895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. To Study Adverse Effect following Immunization (AEFI) and COVID-19 Infection amongst COVID-19 Vaccine Benefeciaries.
    N PP; S CS; F JV; B AB; A KM; T DP; N GC; R IA
    J Assoc Physicians India; 2022 Feb; 70(2):11-12. PubMed ID: 35436817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immediate adverse events following COVID-19 immunization. A cross-sectional study of 314,664 Italian subjects.
    Gianfredi V; Minerva M; Casu G; Capraro M; Chiecca G; Gaetti G; Mantecca Mazzocchi R; Musarò P; Berardinelli P; Basteri P; Bertini B; Ferri C; Odone A; Signorelli C; Alberti VF; Gastaldi G
    Acta Biomed; 2021 Oct; 92(S6):e2021487. PubMed ID: 34739452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
    Jeon M; Kim J; Oh CE; Lee JY
    J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal.
    Rayamajhi S; Rafi MA; Tripathi N; Dongol AS; Pandey M; Rayamajhi S; Bhandari S; Shrestha P; Hasan MT; Hossain MG
    PLoS One; 2022; 17(8):e0272729. PubMed ID: 35947626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety.
    Glover C; Crawford N; Leeb A; Wood N; Macartney K
    Vaccine; 2020 Jun; 38(31):4892-4900. PubMed ID: 32499067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anxiety-related adverse events following immunization (AEFI): A systematic review of published clusters of illness.
    Loharikar A; Suragh TA; MacDonald NE; Balakrishnan MR; Benes O; Lamprianou S; Hyde TB; McNeil MM
    Vaccine; 2018 Jan; 36(2):299-305. PubMed ID: 29198916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse events following introduction of the ChAdOx1 nCoV-19 vaccine in Somalia in 2021: findings from a fragile setting and implications for the future.
    Hamayoun M; Abdulrazak I; Farid M; Malik MR; Mohamud MF
    IJID Reg; 2022 Sep; 4():47-52. PubMed ID: 35720961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Artificial Intelligence-Enabled Social Media Analysis for Pharmacovigilance of COVID-19 Vaccinations in the United Kingdom: Observational Study.
    Hussain Z; Sheikh Z; Tahir A; Dashtipour K; Gogate M; Sheikh A; Hussain A
    JMIR Public Health Surveill; 2022 May; 8(5):e32543. PubMed ID: 35144240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring the safety of influenza A/H1N1 pandemic and seasonal vaccines in Morocco.
    Tebaa A; Benkirane R; Alj L; Cherkaoui I; Soulaymani-Bencheikh R
    Ther Adv Vaccines Immunother; 2022; 10():25151355221088157. PubMed ID: 35372783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse events following immunization (AEFI): COVID-19 vaccine dose and characteristics in Central Java, Indonesia.
    Wahyudi F; Nugraheni A; Margawati A; Pramono D; Adespin DA; Nugroho TW; Pramana C
    Germs; 2023 Mar; 13(1):40-49. PubMed ID: 38023961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 vaccine acceptance, hesitancy, and determinants among physicians in a university-based teaching hospital in Thailand.
    Sirikalyanpaiboon M; Ousirimaneechai K; Phannajit J; Pitisuttithum P; Jantarabenjakul W; Chaiteerakij R; Paitoonpong L
    BMC Infect Dis; 2021 Nov; 21(1):1174. PubMed ID: 34809607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.
    Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL
    Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse events following immunization of ChAdOx1 nCoV-19 vaccine among healthcare workers of a medicine-teaching institution of North India.
    Jha A; Kumar P; Goel SK; Bharatwal AA; Dhamnetiya D; Singh S; Jha RP
    J Family Med Prim Care; 2024 Jan; 13(1):298-310. PubMed ID: 38482279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cohort event monitoring to determine the adverse events following administration of mouse brain derived, inactivated Japanese Encephalitis vaccine in an endemic district in Sri Lanka.
    De Alwis KN; Abeysinghe MR; Wickramesinghe AR; Wijesinghe PR
    Vaccine; 2014 Feb; 32(8):924-30. PubMed ID: 24406391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.